Three-fourths of patients have 70-75% improvement at 16 weeks with zasocitinib, envudeucit ...

CHICAGO, IL, UNITED STATES, March 30, 2026 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) welcomed more ...

Confused between eczema and psoriasis? Experts explain how these skin conditions differ in symptoms, causes, and treatment.

A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...

Combining traditional dermatopathology with PCR-based molecular testing improves diagnostic accuracy in differentiating ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Nonsteroidal topicals like roflumilast are enabling proactive, long-term psoriasis control across a broad range of patients, ...

With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its ...

Psoriasis may be associated with increased risk for postoperative complications among patients undergoing total hip arthroplasty.

"I was very ashamed. I felt like everywhere people were judging me," Amber Dean tells PEOPLE, recalling when her symptoms were at their worst ...

The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to ...